Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan

Table 3 Distribution of CYP1A1*2C, GSTP1A313G, and GSTM1/GSTT1 between CML patients and control

Genotype	CML (n = 99)	Control (n = 169)	P value	OR (95% CI)
CYP1A1 genotype
AA	63 (64)	137(81)
AG	15 (15)	15(9)	0.006	2.686(1.326–5.440)
GG	21 (21)	17(10)	0.666	1.235(0.473–3.225)
GSTP1 genotype
Ile/Ile	51 (52)	142(84)
Ile/Val	36 (36)	6(4)	0.242	1.591(0.731–3.464)
Val/Val	12 (12)	21(12)	0.001	0.095(0.031–0.291)
GSTM1/GSTT1
Normal	36 (36.4)	76(46)
M deletion	36 (36.4)	55(33)	0.747	0.844(0.303–2.357)
T deletion	21 (21.2)	23(13)	0.351	0.611(0.217–1.722)
Double deletion	6 (6)	15(8)	0.147	0.438(0.143–1.338)
Combined genotype^a
AA + Ile/Val	27 (27)	7 (4.2)	0.001	8.679(3.613–20.849)
AG + Ile/Val	6 (6)	0	0.023	-
AG + M Deletion	3 (3)	0	0.024	-
GG + T Deletion	6 (6)	2 (1.2)	0.042	5.387(1.066–27.229)
Ile/Val + Normal	12 (12)	2 (1.2)	0.001	11.517(2.521–52.618)
Ile/Val + M deletion	12 (12)	5 (3)	0.006	4.524(1.544–13.258)
Ile/Val + T deletion	21(12)	4 (2.4)	0.001	4.106(3.687–33.452)

^a Only statistically significant genotype combinations are included for details see supplementary Table 1

ISSN: 1471-2407